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Abstract
Objective. To measure the long-term rate of radiographic progression in a cohort of patients treated early
vs late with conventional DMARDs.
Methods. The long-term rate of radiographic progression in patients included in the Swiss clinical quality
management in rheumatoid arthritis (SCQM-RA) registry who initiated treatment with conventional
DMARDs within the first year of symptom onset (early DMARD) vs patients who initiated treatment
15 years after symptom onset (late DMARD). Radiographic progression was assessed in 38 joints
using a validated score (Ratingen Score). The rate of progression was calculated using a multivariate
regression model for longitudinal data, adjusting for potential confounders.
Results. A total of 970 RA patients were included. The 368 patients in the early DMARD group started
therapy after a median symptom duration of 6 months, whereas the 602 patients in the late DMARD group
initiated therapy after median 2.5 years. RF, MTX use and other risk factors for erosive disease progres-
sion were similar between the two groups. However, the estimated rate of radiographic progression at
baseline was higher in the early DMARD vs the late DMARD group (1.8 vs 0.6, P< 0.01). In spite of this,
the long-term rate of radiographic progression was significantly lower in the early DMARD group after
adjustment for confounding factors (0.35 at 5 years, P= 0.012).
Conclusion. This result supports the concept of a therapeutic window of opportunity early in the disease
course and suggests that early initiation of DMARD therapy results in a long-lasting reduction of radio-
graphic damage.
Key words: Rheumatoid arthritis, Anti-rheumatic therapy, Radiographic progression, Disease-modifying
anti-rheumatic drug, Cohort, Swiss clinical quality management in rheumatoid arthritis, Therapeutic window.
Introduction
RA is a chronic autoimmune disease characterized by
chronic inflammation and destructive changes of the
joints, resulting ultimately in physical disability. Treatment
is based on drugs that reduce inflammation and slow the
progression of joint damage, the so-called DMARDs.
Seminal studies have shown that early initiation of
DMARD treatment can have a lasting benefit [13].
Whereas several trials have established the short-term
benefits of early initiation of DMARD treatment, the data
on the long-term effects on the disease course are some-
what controversial. Some studies demonstrated persistent
effects on radiographic progression, others did not
[2, 47]. A recent meta-analysis of the literature showed
that the long-term rates of radiographic progression were
significantly lower in patients starting DMARDs early as
compared with patients starting later [8]. However, no ran-
domized controlled trial comparing early vs late therapy
with similar DMARD regimens have been performed. In
this study, we analysed the rates of long-term radiographic
progression in a large patient cohort with regard to the
latency between symptom onset and DMARD initiation.
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Patients and methods
Study design
This is a longitudinal, observational, population-based
cohort study nested within the Swiss Clinical Quality
Management for Rheumatoid Arthritis (SCQM-RA)
registry.
Study population
The SCQM-RA registry is a longitudinal cohort of RA pa-
tients, which has been described in detail elsewhere [9].
Inclusion criteria for this study were a diagnosis of RA
established by a board-certified rheumatologist, enrol-
ment in the SCQM-RA within 5 years of symptom onset,
simultaneous initiation of a DMARD therapy and availabil-
ity of sequential radiographs since enrolment. Exclusion
criteria were the absence of DMARD therapy during
the first 5 years of symptom onset. We further excluded
from the primary analysis patients who started their
anti-rheumatic therapy with a biologic agent, because
we felt that these patients represent a subgroup with
very severe disease, not representative of the overall RA
population. We included all patients of the database cor-
responding to these inclusion and exclusion criteria be-
tween January 1997 and December 2008. Ethical
approval for the collection of patient data for the SCQM
register was given by the regional review boards. Informed
consent was obtained from all patients before inclusion
into the SCQM register.
Outcome of interest
This study’s primary end point was radiographic disease
progression as measured by change from baseline in
radiographic damage scores. We used a validated scoring
method to assess the number and size of juxta-articular
bone erosions (Ratingen Score) [10], which is sensitive to
change and appears less susceptible to ceiling effects in
advanced disease [11].
Exposure of interest and predictors
The exposure of interest for this study was the latency
between symptom onset and DMARD initiation. We pur-
posefully decided to use the notion of symptom onset as
defined by the patient instead of disease onset defined by
the physician, because in most patients RA symptoms
precede the diagnosis by several months or years. We
felt that latency between symptom onset and DMARD ini-
tiation probably better characterizes the notion of thera-
peutic window of opportunity than latency between
diagnosis and DMARD initiation, commonly used in ran-
domized trials. We dichotomized the time delay between
symptom onset and DMARD initiation and arbitrarily
defined two groups:
. early DMARD: if conventional DMARDs were initiated
within 1 year of symptom onset; and
. late DMARD: if conventional DMARDs were initiated
between 1and 5 years of symptom onset.
Conventional DMARDs were defined as MTX, LEF, SSZ
or other conventional DMARDs (HCQ, parenteral Gold,
ciclosporin). We excluded glucocorticoid monotherapy
from this definition, as glucocorticoid monotherapy
tends to be given to patients with milder forms of the dis-
ease. Important predictors of RA disease progression
such as measures of disease activity, self-assessed
symptom questionnaires, various disease characteristics,
demographic characteristics and treatment information
were extracted from the database to be used in the ana-
lysis. Another predictor was the estimated yearly rates of
radiographic progression at baseline, which was com-
puted by dividing the radiographic scores at baseline by
the disease duration [12]. We determined the time span in
years for which each individual DMARD regimen had been
used during follow-up and used this variable to control the
analysis for DMARD use. Disease characteristics and
other covariates were extracted from the SCQM-RA data-
base. For sporadically missing covariates, which never
exceeded 5% of any given covariate, we used population
means.
Statistical analysis
Baseline disease characteristics were compared between
two groups using adequate descriptive statistics. All stat-
istical tests were two-sided and evaluated at the 0.05 sig-
nificance level. The statistical analysis was performed with
Stata version 9.2 for Windows (Stata Statistical Software,
College Station, TX, USA).
The relationship between delay in DMARD initiation and
radiographic progression could potentially be confounded
by differences in disease characteristics and in treat-
ments. We therefore used multivariate longitudinal
regression and adjusted for potential confounding factors
[13]. RF, baseline disease activity [28-joint DAS (DAS-28)],
baseline functional disability (HAQ), baseline estimated
rates of radiographic damage progression, age, sex,
socio-economic status (educational level) and co-therapy
with MTX, LEF, SSZ, other DMARDs, no DMARDs or
glucocorticoids were considered confounders a priori
and forced into the model. We further explored effect
modification by RF positivity, concomitant glucocortic-
oids, concomitant MTX and estimated baseline radio-
graphic progression. Patients who started their DMARD
therapy straight with a biological agent were excluded.
However, a sensitivity analysis with these patients was
performed, comparing early biologic vs late biologic
initiation.
Results
A total of 970 patients corresponding to the study criteria
could be included. The average follow-up time was
4 years, with a median of three sequential X-rays of
hand and feet. Within 1 year of symptom onset, 368 pa-
tients were started on DMARD treatment, with a median
time of 6 months. In the late DMARD group, therapy was
initiated after a median time of 2.3 years (range 15 years).
At baseline, no significant differences between the two
groups were noted for age, sex, RF-positivity and
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educational level (Table 1). Disease activity was signifi-
cantly higher in the early DMARD group at baseline, con-
sistent with a higher estimated rate of radiographic
progression at baseline in this group. MTX was the most
commonly prescribed first DMARD (>80%) and it was
prescribed with the same frequency in both groups.
Significantly more patients in the late DMARD group
were on LEF and HCQ, reflecting a higher percentage of
patients receiving combination DMARD treatment in the
late DMARD group. On the other hand, significantly more
patients in the early group were treated with concomitant
glucocorticoids (65 vs 49%). As expected, the erosion
score (ERO, Ratingen score) at baseline was significantly
higher in the late DMARD group compared with the early
DMARD group (median 1.4 vs 0.9, P< 0.01). However, the
estimated rate of ERO progression at baseline was higher
in the early DMARD group, suggesting that the early
DMARD group had a more severe disease.
The primary outcome was radiographic joint damage
progression as measured by the change in Ratingen
score. The unadjusted slopes of radiographic progression
differed between the two groups (P= 0.012), with less
damage progression in the early DMARD group. When
the results were adjusted for potential confounding fac-
tors, radiographic progression in the early DMARD group
remained significantly lower compared with the late
DMARD group (P< 0.001, Fig. 1). Four years after symp-
tom onset, the mean radiographic progression was
0.31%/year (95% CI 0.49, 0.13) higher in the late
DMARD group compared with the early group. The bene-
ficial effect of early DMARD treatment was significantly
higher in patients with high levels of estimated radio-
graphic progression at baseline [additional decrease in
long-term damage progression by 0.19%/year (95% CI
0.26, 0.12); P< 0.0001 in the highest quartile]. Neither
RF positivity nor co-medication with glucocorticoids mod-
ified significantly the effect of early DMARD treatment.
However, patients treated with glucocorticoids tended to
have more rapid radiographic progression than patients
not receiving glucocorticoids. This probably reflects the
fact that concomitant glucocorticoid therapy is an indica-
tor of severe disease. Treatment with MTX as opposed
to other conventional DMARDs did not modify the
TABLE 1 Baseline characteristics of patients treated early versus late with DMARDs
Baseline disease characteristics
Early DMARD
(n=368)
Late DMARD
(n=602) P-value
Symptom duration, median, years 0.5 2.3 a
Female sex, n (%) 71 73 0.41
Age, mean, years 55 54 0.15
RF+, n (%) 64 68 0.19
ERO at inclusion,a median 0.9 1.4 <0.01
Estimated baseline rate of ERO progressiona 1.8 0.6 <0.01
Disease activity (DAS-28), median 4.7 4.1 <0.01
Functional disability (HAQ), median 1 0.8 0.04
Educational level, median, years 12 12 0.18
First DMARD (51 drug allowed), n (%)
MTX, 83 80 0.27
LEF 7 16 <0.01
SSZ 14 19 0.02
HCQ 9 16 <0.01
Combination DMARDs 11 26 <0.01
Concomitant glucocorticoid use, n (%) 65 49 <0.01
aERO and ERO progression (median) are indicated as the percentage of the maximum Ratingen score. The population
averages are expressed in means, if not indicated otherwise.
FIG. 1 Progression of ERO (Ratingen score) over time in
early vs late DMARD-treated patients. Mean EROs (S.E.M.)
are shown as percentages of maximum damage score as
a function of time since symptom onset. Regression
analysis with adjustment for risk factors for radiographic
progression revealed a significant difference in the
slopes of the two curves.
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relationship between early DMARD and late DMARD, sug-
gesting that the type of DMARD treatment was not de-
cisive for the outcome. An exploratory analysis of patients
starting their anti-rheumatic treatment with a biologic
agent revealed similar trends for long-term reduction of
radiologic progression in the early treatment group (data
not shown).
Discussion
In this cohort study, we found a significantly lower pro-
gression rate in RA patients treated early with DMARDs
compared with later, which was not explained by differ-
ences in anti-rheumatic treatment regimen or other differ-
ences in disease characteristics. The benefit of early
DMARD intervention was significantly greater in patients
with high radiographic progression at baseline. Our data
suggest that early DMARD treatment offers a long-term
benefit on joint damage progression and supports the
concept of a therapeutic window of opportunity early in
disease.
A large meta-analysis of 1435 patients suggested that
disease duration at the start of DMARD treatment was the
main predictor of a clinical response to therapy [14]. While
the short-term benefit of early DMARD treatment is well
established, only few studies have shown a benefit of
early therapy on long-term radiographic progression and
no randomized trial has compared early vs late treatment
with a similar DMARD regimen. The present analysis con-
firms similar findings in smaller follow-up studies [45]. In
spite of a higher estimated rate of radiographic progres-
sion at baseline, the early DMARD cohort had a signifi-
cantly lower progression rate over 5 years compared with
the late DMARD group. This difference was also not ex-
plained by variations in anti-rheumatic therapy, as there
were no substantial differences in DMARD use between
the groups and >80% of patients in both groups were
treated with MTX. In an exploratory analysis, we examined
only patients treated with MTX and found a similar trend,
with no evidence for effect modification by the type of
conventional DMARD. Overall 22% of the patients even-
tually started anti-TNF agents over time and the propor-
tion of anti-TNF initiation was similar in the early and late
DMARD groups (P= 0.91). Also, there were no differences
in seropositivity with RF between the groups, but we
missed anti-CCP status for a majority of patients.
The absolute radiographic damage at 5 years was sig-
nificantly lower in the early treatment group despite the
fact that the estimated progression rate at baseline was
higher in this group. To explain the differences in radio-
graphic progression, it can be hypothesized that early
suppression of inflammatory processes in the joint may
prevent irreversible steps of the disease pathogenesis.
Several clinical studies have shown that early aggressive
therapy of RA can result in long-term remission [15],
sometimes even DMARD-free remission [16], suggesting
that the disease pathogenesis has been profoundly mod-
ified, resulting in long-term remission and suppression of
radiological progression.
This analysis has potential limitations inherent to the
analysis of observational data. In this study, there was
no control over the treatment assignment of early
DMARD vs late DMARD. Because the most frequent
reason for delayed DMARD initiation is deferred referral
to a rheumatologist [17], substantial confounding by
indication between early and late DMARD is unlikely.
Confounding by indication would most likely bias the re-
sults towards the null, since the most severely affected
patients are likely to consult earlier and be in the early
DMARD group. This was suggested by a higher level of
estimated baseline radiographic progression in the early
DMARD group and higher use of concomitant glucocortic-
oids. While we could adjust our analysis for many import-
ant disease characteristics potentially associated with
radiographic progression, we cannot exclude the possi-
bility of confounding by unmeasured factors. Strengths of
this analysis include a population-based cohort, a system-
atic prospective ascertainment of a wide variety of poten-
tial confounders and longitudinal radiographical data.
In conclusion, we show in a large patient population
with RA that the radiographic progression over 5 years
is significantly lower in patients with early initiation of
DMARD treatment. Our data provide confirmatory evi-
dence of a long-lasting effect of early disease control,
supporting the existence of a therapeutic window of
opportunity early in the development of RA.
Rheumatology key message
. Early DMARD treatment results in long-lasting
decrease of radiographic progression rate.
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